CHO Pharma, Inc. (6586) Stock Price & Analysis
6586 Stock Chart & Stats
- Day’s Range
- TWD 61.80 - TWD 81.60
- 52-Week Range
- TWD 22.75 - TWD 148.50
- Previous Close
- TWD 78.00
- Volume
- N/A
- Average Volume (3M)
- 515.49K
- Market Cap
- TWD 15.88B
- Enterprise Value
- N/A
- Total Cash (Recent Filing)
- TWD 1.96B
- Total Debt (Recent Filing)
- TWD 7.33M
- Price to Earnings (P/E)
- ―
- Beta
- 0.89
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
6586 FAQ
What was CHO Pharma, Inc.’s price range in the past 12 months?
What is CHO Pharma, Inc.’s market cap?
When is CHO Pharma, Inc.’s upcoming earnings report date?
Is CHO Pharma, Inc. overvalued?
Does CHO Pharma, Inc. pay dividends?
What is CHO Pharma, Inc.’s EPS estimate?
How many shares outstanding does CHO Pharma, Inc. have?
Which hedge fund is a major shareholder of CHO Pharma, Inc.?
What is the TipRanks Smart Score and how is it calculated?
Company Description
CHO Pharma, Inc.
CHO Pharma, Inc., a biotechnology firm headquartered in Taipei City, Taiwan, specializes in the research and development of innovative therapeutic solutions. Central to its operations is an advanced glycoengineering platform. This proprietary technology facilitates the creation of several key therapeutic modalities, including SAR-based glycoengineered "biobetters," site-specific antibody-drug conjugates (ADCs), and novel antibodies and vaccines designed to target unique carbohydrate antigens. The company also offers CHOptimax, an innovative in vitro enzymatic single-step process. This technology allows for the precise transformation of unconjugated antibodies into either glycoengineered biobetters or ADCs. CHO Pharma boasts a robust and diverse pipeline of drug candidates spanning various therapeutic areas, all leveraging its glycoengineering expertise. Currently, several programs are in clinical development: CHO-H01 is undergoing Phase I/IIa trials for refractory non-Hodgkin lymphoma, while CHO-A04, a humanized monoclonal antibody, has entered Phase I trials targeting a range of tumor and cancer stem cells. Additionally, CHO-V08 is being developed as a vaccine against Klebsiella pneumoniae. In the preclinical stage, CHO Pharma is advancing CHO-H02, an agent designed to address various solid tumors including breast, bladder, pancreatic, ovarian, and gastric cancers. Another preclinical asset, CHO-H03, is an antibody drug being investigated for inflammatory conditions associated with autoimmune diseases such as rheumatoid arthritis, ulcerative colitis, and Crohn's disease. Established in 2012, CHO Pharma continues to innovate from its base in Taipei City, Taiwan.
- Sector
- General
- Industry
- Biotechnology
- CEO
- Chung-Yi Wu
- Employees
- 35
- Website
- www.chopharma.com
- Address
- Building C, Taipei, TPE, 115202, TW
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 2 | 14 |
| Technical Analysis | 6 | 2 | 2 |
| Moving Averages | 0 | 0 | 12 |

